Atherosclerosis Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Drug Class (Anti-platelet Medications, Cholesterol-Lowering Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Beta Blockers, Others) Distribution Channel and by Geography.

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 2.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The atherosclerosis drugs market studied was projected to grow with a CAGR of 2.2% over the forecast period. The major factor attributing to the growth of the market is the increase in the prevalence of atherosclerosis and cardiovascular diseases. According to the European Heart Network, 2017, every year, cardiovascular disease causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. The maximum incidences of cardiovascular diseases can be attributed to the sedentary lifestyle in developed countries. The sedentary lifestyle leads to a high prevalence of high blood pressure, high cholesterol, obesity, and high alcohol consumption, which together contribute to a high incidence of cardiovascular diseases. Therefore, the sedentary lifestyle leading to a high prevalence of cardiovascular diseases and increasing awareness of the treatment options are expected to drive the market studied.

Scope of the Report

As per the scope of the report, atherosclerosis is a hardening and narrowing of your arteries. It puts blood flow at risk as arteries get blocked. This report is segmented by Drug Class, Distribution Channel and by Geography.

By Drug Class
Anti-platelet Medications
Cholesterol Lowering Medications
Fibric Acid and Omega-3 Fatty Acid Derivatives
Beta Blockers
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cholesterol Lowering Medications Segment is Dominating the Atherosclerosis Drugs Market.

  • Cholesterol-lowering drugs include statins and fibrates. The dominant share of the segment is attributed to the increasing prevalence of cardiovascular disease and high cholesterol, obesity globally. According to the World Health Organization in 2018, an estimated 40 million children under the age of 5 years were overweight or obese. A heightened intake of energy-dense foods that are high in fat and sugars, and an upsurge in physical immobility due to the increasingly inactive nature of many forms of work, changing modes of transportation, and increasing urbanization are factors propelling the high cholesterol rates and ultimately boosting the segment growth. 
  • Furthermore, the approval of novel cholesterol-reducing drugs is enhancing segment growth. For instance, the drugs, alirocumab (Praluent) and evolocumab (Repatha) belong to a new category of medications known as PCSK9 inhibitors which lower harmful LDL cholesterol values dramatically more than 50%. these types of novel treatment drugs boost segment growth. The increasing patient pool and increasing approvals of new drugs enhance the segment growth.
Number of Cardiovascular Diseases Cases(Million), By Year, Global

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of cardiovascular diseases and atherosclerosis, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. About 647,000 Americans die from heart disease each year, 1 in every 4 deaths. Heart disease costs the United States about USD 219 billion each year. As per the statistics, the increasing patient pool and increasing disposable revenue in this country boost the market growth of the region.

Atherosclerosis Drugs Market - Growth Rate by Region

Competitive Landscape

The Atherosclerosis drugs market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Pfizer Inc., AstraZeneca, Merck & Co., Inc., Sanofi US, Amgen Inc., Novartis AG, GlaxoSmithKline Plc, Bayer AG, Mylan N.V., Eli Lilly and Company

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases

      2. 4.2.2 Rising Awareness about Cardiovascular Diseases

    3. 4.3 Market Restraints

      1. 4.3.1 Low Diagnostic Rate

      2. 4.3.2 Availability of Generic Products

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Class

      1. 5.1.1 Anti-platelet Medications

      2. 5.1.2 Cholesterol Lowering Medications

      3. 5.1.3 Fibric Acid and Omega-3 Fatty Acid Derivatives

      4. 5.1.4 Beta Blockers

      5. 5.1.5 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Retail Pharmacies

      2. 5.2.2 Hospital Pharmacies

      3. 5.2.3 Online Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer Inc.

      2. 6.1.2 AstraZeneca

      3. 6.1.3 Merck & Co., Inc.

      4. 6.1.4 Sanofi US and Regeneron Pharmaceuticals, Inc.

      5. 6.1.5 Amgen Inc.

      6. 6.1.6 Novartis AG

      7. 6.1.7 GlaxoSmithKline Plc

      8. 6.1.8 Bayer AG

      9. 6.1.9 Mylan N.V.

      10. 6.1.10 Eli Lilly and Company

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Atherosclerosis Drugs Market market is studied from 2018 - 2026.

The Atherosclerosis Drugs Market is growing at a CAGR of 2.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc., AstraZeneca, Merck & Co., Inc. , Sanofi US, Amgen Inc. are the major companies operating in Atherosclerosis Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!